Drug Profile


Alternative Names: ARN-509; JNJ-56021927; JNJ-927

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator University of California System
  • Developer Case Comprehensive Cancer Center; Institut Paoli-Calmettes; Janssen Research & Development
  • Class Antiandrogens; Antihormones; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists; Hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 17 Mar 2017 Universitaire Ziekenhuizen Leuven plans a phase II trial for Prostate cancer (Neoadjuvant therapy, Combination therapy) (NCT03080116)
  • 08 Feb 2017 Phase-II clinical trials in Prostate cancer (Early-stage disease) in France (PO) (EudraCT2016-001266-29)
  • 06 Feb 2017 Phase-II clinical trials in Prostate cancer (Newly diagnosed, Combination therapy) in USA (PO) before February 2017(NCT02903368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top